07:20 AM EDT, 07/09/2024 (MT Newswires) -- Eli Lilly's ( LLY ) Mounjaro treatment leads to faster and greater weight loss compared to similar drugs that use semaglutide as the main ingredient, including Novo Nordisk's ( NVO ) Wegovy, according to a data analysis published on Monday in JAMA Internal Medicine.

The cohort study assessed weight outcomes for overweight or obese adults receiving semaglutide -- the main ingredient in Wegovy and Ozempic, or tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound --between May 2022 and September 2023. The patients were identified using electronic health record data linked to dispensing information from a collective of US health care systems.

Results indicated "individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss and larger reductions in body weight compared with those treated with semaglutide," according to the study.

Novo Nordisk ( NVO ) shares were down 1.7% in pre-market trading, while Eli Lilly ( LLY ) was 0.5% higher.

Price: 141.05, Change: -2.02, Percent Change: -1.41